Al-Ali Firas, Elias John J, Tomsick Thomas A, Liebeskind David S, Broderick Joseph P
From the Departments of Neuro-Interventional Surgery (F.A.-A.) and Research (J.J.E.), Akron General Medical Center, OH; Department of Radiology, University of Cincinnati Academic Health Center, OH (T.A.T.); Neurovascular Imaging Research Core & UCLA Department of Neurology, Los Angeles, CA (D.S.L.); and Department of Neurology, University of Cincinnati Academic Health Center, OH (J.P.B.).
Stroke. 2015 Jun;46(6):1590-4. doi: 10.1161/STROKEAHA.115.009066. Epub 2015 May 7.
Until recently, acute ischemic stroke (AIS) trials have failed to show a benefit of endovascular therapy compared with standard therapy, leading some authors to recommend decreasing the time from ictus to revascularization to improve outcomes. We hypothesize that improving patient selection using the capillary index score (CIS) may also be a useful strategy.
CIS was calculated, blinded to outcome, from pretreatment diagnostic cerebral angiograms for 78 subjects in the Interventional Management of Stroke III database with internal carotid artery and middle cerebral artery trunk occlusion. The CIS was dichotomized into favorable (fCIS=2 or 3) and poor (pCIS=0 or 1). Outcomes were categorized based on the modified Rankin Scale score at 90 days (0-2 considered a good outcome). Modified thrombolysis in cerebral infarction score 2b or 3 was considered good revascularization. Multivariable logistic regression was performed to relate CIS, time from ictus to revascularization, modified thrombolysis in cerebral infarction score, and National Institue of Health Stroke Scale score to good outcomes.
Only CIS and modified thrombolysis in cerebral infarction scores were correlated with good outcomes (P<0.01). Patients with fCIS and good revascularization achieved 71% modified Rankin Scale≤2, compared with 13% for patients with pCIS and good revascularization.
In this subset of patients from the Interventional Management of Stroke III Trial, CIS and modified thrombolysis in cerebral infarction were strong predictors of outcome after endovascular reperfusion. Using the CIS to improve patient selection could be a powerful strategy to improve rate of good outcomes in endovascular therapy. A randomized trial is needed.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359424.
直到最近,急性缺血性卒中(AIS)试验仍未显示血管内治疗相较于标准治疗有何益处,这使得一些作者建议缩短从发病到血管再通的时间以改善预后。我们推测,使用毛细血管指数评分(CIS)改善患者选择可能也是一种有用的策略。
对卒中干预管理III数据库中78例颈内动脉和大脑中动脉主干闭塞的受试者,在不知晓结果的情况下,根据治疗前诊断性脑血管造影计算CIS。将CIS分为良好(fCIS = 2或3)和不良(pCIS = 0或1)。根据90天时的改良Rankin量表评分(0 - 2被视为良好预后)对结果进行分类。改良脑梗死溶栓评分2b或3被视为良好的血管再通。进行多变量逻辑回归,以将CIS、从发病到血管再通的时间、改良脑梗死溶栓评分和美国国立卫生研究院卒中量表评分与良好预后相关联。
只有CIS和改良脑梗死溶栓评分与良好预后相关(P < 0.01)。fCIS且血管再通良好的患者改良Rankin量表评分≤2的比例达71%,而pCIS且血管再通良好的患者这一比例为13%。
在卒中干预管理III试验的这部分患者中,CIS和改良脑梗死溶栓是血管内再灌注后预后的有力预测指标。使用CIS改善患者选择可能是提高血管内治疗良好预后率的有力策略。需要进行一项随机试验。